A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination with Ipilimumab and Nivolumab in Patients with Unresectable Stage III or Stage IV Melanoma
Brief description of study
The main purpose of this study is to test the safety, tolerability, and effectiveness of the study drug tocilizumab when given with the drugs ipilimumab and nivolumab to patients with stage III or stage IV melanoma that cannot be removed by surgery.
Clinical Study Identifier: s19-00008
ClinicalTrials.gov Identifier: NCT03999749
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
